Clearpoint Neuro Inc

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ClearPoint Neuro reports revenue growth, faces margin pressures in 2022

ClearPoint Neuro's financial performance in 2022 showed revenue growth but faced margin pressures and increased operating expenses.
The company's strengths lie in revenue growth projections, successful product launches, and cost-saving initiatives.
Challenges include post-COVID operational disruptions, supply chain concerns, and achieving cash breakeven targets.
Opportunities exist in R&D investments, international expansion, and maintaining an optimistic outlook for future growth.

ClearPoint Neuro reports Q1 growth, targets $50M revenue by 2025

ClearPoint Neuro Inc's Q1 performance reflects steady revenue growth and strategic investments to drive future expansion and innovation.
While facing challenges in certain revenue segments and margin decline, the company's strong growth strategy and focus on key areas present opportunities for sustained success.
With a clear roadmap to achieve revenue targets, expand partnerships, and launch new products, ClearPoint is poised for continued growth and market leadership in the neurosurgery sector.

ClearPoint Neuro reports record revenue and growth strategy focus

ClearPoint Neuro Inc's Q2 2023 earnings call highlighted record revenue, growth pillars, and operational efficiency improvements. Challenges include installation barriers and regulatory expansions, while opportunities lie in neuro-oncology expansion and pharma partnerships. The company aims for cash flow breakeven by 2025 and emphasizes long-term pharma relationships.

ClearPoint Neuro reports improved Q3 performance amidst strategic growth plans

ClearPoint Neuro's Q3 2023 performance showed improvements in operational cash burn and revenue growth in key segments, despite challenges in gross margin and operating expenses.
The company's strategic focus on innovation, patient outcomes, and market expansion presents opportunities for sustained growth and competitiveness in the healthcare sector.
While facing challenges in cost management and market access, ClearPoint Neuro is well-positioned to leverage opportunities in new revenue streams, product launches, and operational enhancements.
Overall, ClearPoint Neuro's commitment to improving patient outcomes, expanding market reach, and driving innovation underscores its potential for future success and growth.

ClearPoint Neuro reports robust Q4 earnings, eyes growth opportunities

ClearPoint Neuro's strong Q4 performance and revenue growth in 2023 position the company well for 2024. Despite challenges with EU MDR certification, ClearPoint is investing in partnerships to overcome regulatory hurdles. Opportunities for growth include new product releases and expanding market presence.

ClearPoint Neuro reports 41% revenue growth in Q1 2024

ClearPoint Neuro's Q1 2024 earnings call showcased robust revenue growth, controlled expenses, and a strategic focus on key growth areas. The company's optimistic outlook for 2024 is supported by strong demand from pharmaceutical partners and expansion initiatives.

ClearPoint Neuro reports record revenue growth and raises full-year guidance

ClearPoint Neuro's Q2 2024 performance reflects robust revenue growth and a solid financial position.
The company's focus on key growth pillars and increased revenue guidance for the year signal a positive outlook for future expansion.
While challenges in cost management and market competition exist, ClearPoint Neuro's strengths and opportunities position it well for sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRVINE, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a medical device company with a portfolio of products focused on enabling therapies for neurological disorders, today announced financial results for its third fiscal quarter ended September 30, 2020.

ClearPoint Neuro Reports Third Quarter 2020 Results

News for Clearpoint Neuro Inc Stock (CLPT)